Archive · 23 Dec 2025
Emcure Launches Povistra for Obesity Market
Emcure Pharmaceuticals has introduced a new weightloss drug called Povistra in India.
This drug is similar to a popular medicine called Wegovy and helps people manage their weight.
It comes in different strengths and is priced at ₹8,790 per month.
The drug is meant for adults who are obese or overweight with certain health conditions.
Emcure hopes to help many people in India who are struggling with weight issues, as obesity is linked to many serious health problems.
The company wants to make this treatment widely available across the country.
However, other companies are preparing to launch cheaper versions of the same drug, which could make the market more competitive.
Emcure is focusing on building brand awareness and expanding its reach, especially in smaller cities, through education and awareness programs.
Emcure Pharmaceuticals launched Povistra, a weightloss drug based on semaglutide injection, in India.
Povistra is available in five strengths and priced starting at ₹8,790 per month (₹2,200 weekly).
The drug is indicated for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with comorbidities.
Povistra also aims to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease.
Emcure aims to address India's obesity crisis, with 254 million people living with generalized obesity and 351 million with abdominal obesity.
- Who
- Emcure Pharmaceuticals in partnership with Novo Nordisk
- What
- Launched Povistra, a weightloss drug based on semaglutide injection
- When
- December 22, 2025
- Where
- India
- Why
- To address India's obesity crisis and provide advanced weight management therapy
Innovator Product Advantage
Generic Competition
Market Dominance
Innovator Product Advantage
Innovator products like Povistra will maintain market dominance despite patent expiry, similar to the insulin market.
Generic Competition
Generic versions of semaglutide will capture significant market share due to lower prices.
- Company
- Emcure Pharmaceuticals
- Product
- Povistra (semaglutide injection)
- Indication
- Chronic weight management and cardiovascular risk reduction
- Strengths
- 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg
- Price
- Starting ₹8,790 per month (₹2,200 weekly)
- Target BMI
- ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight with comorbidities)
- Obesity Statistics
- 254 million with generalized obesity, 351 million with abdominal obesity in India
- Patent Expiry
- March 2026
- Competitors
- Sun Pharma, Dr Reddy’s, Natco
- Market Potential
- Estimated to become a billion-dollar market in India by 2030
- Distribution Strategy
- Deployment of 1,000 sales personnel across cardiology, women’s health, internal medicine, and endocrinology
- Awareness Initiative
- Winning Over Obesity platform for consumer and doctor education
Sources
Emcure launches Povistra, second brand of Novo Nordisk’s weightloss drug Wegovy
Emcure launches Rs 8,790 a month semaglutide weight-loss drug in India
Emcure pushes into obesity segment with Poviztra, priced at ₹2,200 weekly
Emcure Pharma launches weight loss drug
Pill version of Wegovy is approved for use in the US
FDA approves daily pill version of Novo Nordisk’s weight-loss drug Wegovy – How much will it cost?
Wegovy Weight Loss Pill Gets US FDA Nod: A New Era In Obesity Treatment?
Emcure sets sights on pan-Indian obesity market with Poviztra
